search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Biologicals and tsDMARDs in inflammatory rheumatic diseases: The Reade Rheumatology Registry


- candidate number28244
- NTR NumberNTR6868
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR21-nov-2017
- Secondary IDsP1660 METC Slotervaartziekenhuis en Reade
- Public TitleBiologicals and tsDMARDs in inflammatory rheumatic diseases: The Reade Rheumatology Registry
- Scientific TitleBiologicals and tsDMARDs in inflammatory rheumatic diseases: The Reade Rheumatology Registry
- ACRONYM
- hypothesis
- Healt Condition(s) or Problem(s) studiedInflammatory rheumatic disease, Targeted synthetic DMARD (tsDMARD), Biological
- Inclusion criteria- Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis/non-radiographic axial spondyloarthritis, according to the treating rheumatologist;
- Written informed consent.
- Exclusion criteriaNone
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeobservational
- planned startdate 24-nov-2016
- planned closingdate
- Target number of participants0
- Interventionsnone
- Primary outcomeEfficacy will be determined in comparison to baseline by comparing disease activity, patient reported outcomes, radiological progression and functional capacity during follow-up.
Safety will be determined by the occurrence of side effects.
- Secondary outcomeChanges in (bio)markers during treatment will be analyzed versus baseline.
- TimepointsBaseline (prior to treatment) and 1 month, 3-4 months, 6-7 months, 1 year, 1,5 year, 2 years and yearly thereafter.
- Trial web sitewww.reade.nl and www.ams.rc.com
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD. PhD. M.T. Nurmohamed
- CONTACT for SCIENTIFIC QUERIESMD. PhD. M.T. Nurmohamed
- Sponsor/Initiator Reade Center for Rehabilitation and Rheumatology
- Funding
(Source(s) of Monetary or Material Support)
Reade Center for Rehabilitation and Rheumatology
- Publications
- Brief summaryRationale: 1) Biologicals and targeted synthetic Disease Modifying AntiRheumatic Drugs (tsDMARD) are approved in the Netherlands for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS)/non-radiographic axial spondyloarthritis (nrAxSpA). As efficacy in daily clinical practice can differ from the clinical (registration) trials, e.g. due to different patient groups, it is important to monitor the daily clinical practice. 2) Nowadays treatment of RA, PsA and AS (nrAxSpA) is to a large extent protocolized and aimed at achieving remission. After achieving remission it is important to taper or even stop the antirheumatic drugs to avoid unnecessary drug exposure. Identifying (bio)markers for treatment response, failure and successful tapering will improve treatment response.

Objective: To determine the efficacy and safety of biological agents and tsDMARDs in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients in daily clinical practice. In addition, prognostic (bio)markers for treatment response, failure and successful tapering will be identified.

Study design: Prospective observational cohort study in patients with RA, PsA, AS (nrAxSpA) who are treated with biologics or tsDMARDs or in whom treatment with these agents is initiated. Efficacy and safety data will be collected throughout the study.

Main study parameters: Efficacy will be determined in comparison to baseline by comparing disease activity, patient reported outcomes, radiological progression and functional capacity during follow-up.
Safety will be determined by the occurrence of side effects. Changes in (bio)markers during treatment will be analyzed versus baseline.
- Main changes (audit trail)
- RECORD21-nov-2017 - 15-dec-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl